News
Korean preclinical CRO CorestemChemon is expanding its offerings through a partnership with ATG Lifetech, with the goal of ...
The FDA is amplifying an effort underway at the medical device distributor Medline, which aims to correct certain ...
Sanofi tightens grip on RSV, paying $1.15B upfront for Vicebio and boosting its pipeline beyond mRNA
Sanofi has struck a deal to buy Vicebio for $1.15 billion upfront, securing preclin | Sanofi has struck a deal to buy Vicebio ...
Scancell has linked iSCIB1+ to a 69% response rate in advanced melanoma, lead | Scancell has linked iSCIB1+ to a 69% response ...
The FDA has rejected Replimune’s request for approval of RP1, adding the melanoma drug candidate to the list of assets to ...
The portable MRI manufacturer Hyperfine has begun rolling out the next generation of its artificial intelligence-equipped scanner-on-wheels, following an FDA green light last month. | The Fierce ...
Medtronic has secured a new approval in Europe, greatly expanding the reach of its MiniMed 780G pump system—including for ...
Alkermes outlined plans to move its NT1 drug candidate, alixorexton, into phase 3 after posting results from the midstage ...
The Sarepta saga continues, with the FDA slapping a clinical hold across all of the company’s investigational limb girdle ...
Concentra Biosciences is living up to its reputation of buying beleaguered biotechs, this time swooping in to grab iTeos ...
The three-year-old spinout from Zimmer Biomet has reached the end of its road. | The three-year-old spinout from Zimmer ...
Roche’s hopes of getting its chronic obstructive pulmonary disease (COPD) drug astegolimab to regulators this year have taken ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results